Origin of the Name "Mounjaro"
The provided medical evidence does not contain information about the etymology or naming origin of Mounjaro (tirzepatide). The available studies and guidelines focus exclusively on the medication's clinical efficacy, safety profile, mechanism of action, and prescribing information, but do not address why Eli Lilly chose the brand name "Mounjaro" for this dual GIP/GLP-1 receptor agonist.
The evidence confirms that:
- Tirzepatide is marketed under the brand name Mounjaro™ for type 2 diabetes management 1
- It is a novel dual glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 receptor agonist 1
- The medication was developed and is manufactured by Eli Lilly 1
To obtain accurate information about the naming origin, you would need to consult Eli Lilly's corporate communications, press releases from the time of FDA approval, or pharmaceutical branding/marketing literature, as this information falls outside the scope of clinical medical evidence.